Comparator: laropiprant

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HypercholesterolemiaMixed HyperlipidemiaPrimary HypercholesterolemiaType 2 Diabetes Mellitus

Phase 1

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

CompletedNCT00618995

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2007-08-31End: 2007-12-31Updated: 2015-09-07

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

CompletedNCT00769132

Merck Sharp & Dohme LLCHypercholesterolemia

Start: 2007-08-03End: 2007-11-06Updated: 2019-11-21

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

CompletedNCT01012219

Merck Sharp & Dohme LLCMixed Hyperlipidemia, Primary Hypercholesterolemia

Start: 2009-11-30End: 2010-04-30Updated: 2015-11-02